RSS feed (help and list of feeds)
Consultation
We ask for feedback on proposals through public consultation, and take into account all consultation responses we receive before making our decisions. PHARMAC has published guidance for consumers on getting involved in our decisions, and this includes responses to consultation. You can download the document here (8 pages, 100 KB).
We welcome feedback from pharmaceutical suppliers, health professionals, health interest groups and the general public. This page includes consultations that are currently underway.
You can respond to consultation by writing to the address at the bottom of the consultation letter.
Rapid response
If you would like to make a rapid response to any of our consultations, click 
here. Remember to indicate which consultation proposal your comments relate to.
Search for previous consultation documents
- Proposal for funding of various Janssen-Cilag products. Closes Monday, 13 September 2010 (5 pages, 171 KB) 27 Aug 2010
- Proposal regarding insulin pen needles and disposable insulin syringes. Closes Friday, 10 September 2010 (2 pages, 55 KB) 27 Aug 2010
- Proposal relating to the funding of travoprost. Closes Monday, 6 September 2010 (2 pages, 50 KB) 24 Aug 2010
- Proposal relating to venlafaxine, etanercept, varenicline & sunitinib. Closes Friday, 3 September 2010 (14 pages, 95 KB) 19 Aug 2010
- Consultation on Influenza vaccine proposals. Closed (3 pages, 47 KB) 10 Aug 2010
- Proposal to list new brand of sodium chloride in Section H. Closed (2 pages, 151 KB) 09 Aug 2010
- Consultation on the listing of various pharmaceuticals on the Pharmaceutical Schedule. Closed (3 pages, 59 KB) 05 Aug 2010
- Consultation on various Special Food funding proposals. Closed (4 pages, 63 KB) 30 Jul 2010
- Proposal for radiological contrast media. Closed (2 pages, 117 KB) 30 Jul 2010
- Proposal to fund a new topical anti-acne treatment (adapalene). Closed (2 pages, 57 KB) 30 Jul 2010
- Proposal to fund erlotinib and widen access to rituximab, capecitabine and mycophenolate. Closed (15 pages, 112 KB) 30 Jul 2010
- Proposal to list a new brand of sodium chloride in Section H. Closed (1 page, 49 KB) 30 Jul 2010
- Proposal to reference price loperamide hydrochloride presentations. Closed (2 pages, 50 KB) 30 Jul 2010
- Proposal to widen access to temozolomide. Closed (2 pages, 150 KB) 29 Jul 2010
- Consultation letter - Ezetrol, Vytorin, Tolvon, Ovestin. Closed (6 pages, 98 KB) 27 Jul 2010
- Proposal to fund modafinil (Modavigil) for narcolepsy. Closed (2 pages, 108 KB) 23 Jul 2010
- Proposal to list various API Consumer Brands products in the Pharmaceutical Schedule. Closed (2 pages, 147 KB) 16 Jul 2010
- Tender 2010 - letter to Medical Groups, DHB Hospital Pharmacies and interested parties - closed (25 pages, 407 KB) 14 Jul 2010
- Tender 2010 - letter to pharmaceutical suppliers and interested parties - ACPs closed, other responses closed (26 pages, 326 KB) 14 Jul 2010
- Proposal to fund meloxicam and mitomycin. Closed (3 pages, 56 KB) 12 Jul 2010
Page updated on 01 Sep 2010
Linked documents
Having Your Say in our Decisions (8 pages, 100 KB)
Pharmaceutical Management Agency Having your say in our decisions PHARMAC’s decision-making PHARMAC is the Government agency that decides which medicines are funded for New Zealanders. We welcome input from people into our decision-making processes. There are a number of ways…
Proposal for funding of various Janssen-Cilag products. Closes Monday, 13 September 2010 (5 pages, 171 KB)
27 August 2010 Proposal relating methylphenidate to darunavir, etravirine, doripenem and PHARMAC and Janssen-Cilag Pty Ltd have entered into a provisional agreement that would result in the funding of two new antiretrovirals, a new hospital antibiotic and amending the terms…
Proposal regarding insulin pen needles and disposable insulin syringes. Closes Friday, 10 September 2010 (2 pages, 55 KB)
27 August 2010 Proposal regarding insulin pen needles and disposable insulin syringes PHARMAC is seeking feedback on a proposal to: • • fully fund a new, finer gauge insulin pen needle (32 g x 4 mm); and amend the terms…
Proposal relating to the funding of travoprost. Closes Monday, 6 September 2010 (2 pages, 50 KB)
24 August 2010 Proposal relating to the funding of travoprost PHARMAC is seeking feedback on a proposal relating to a provisional agreement with Pharmaco (NZ) Ltd for the glaucoma treatment, travoprost (Travatan). This proposal would mean that reference pricing would…
Proposal relating to venlafaxine, etanercept, varenicline & sunitinib. Closes Friday, 3 September 2010 (14 pages, 95 KB)
19 August 2010 Proposal relating to venlafaxine, etanercept, varenicline & sunitinib PHARMAC is seeking feedback on a proposal to: • • • • change the terms of listing of venlafaxine (Efexor XR); widen access to etanercept (Enbrel) to include the…
Consultation on Influenza vaccine proposals. Closed (3 pages, 47 KB)
10 August 2010 Proposals for influenza vaccine PHARMAC is seeking feedback on a proposal to list two brands of influenza vaccine in the Pharmaceutical Schedule for the 2011, 2012, and 2013 influenza seasons. In summary, this proposal would result in:…
Proposal to list new brand of sodium chloride in Section H. Closed (2 pages, 151 KB)
9 August 2010 Proposal to list new brand of sodium chloride in Section H PHARMAC is seeking feedback on a provisional agreement it has reached with Multichem NZ Limited. In summary, this proposal would result in: § Listing of the…
Consultation on the listing of various pharmaceuticals on the Pharmaceutical Schedule. Closed (3 pages, 59 KB)
05 August 2010 Consultation on the listing of various pharmaceuticals on the Pharmaceutical Schedule PHARMAC is seeking feedback on a proposal to list various pharmaceuticals in Section B and Part II of Section H of the Pharmaceutical Schedule and to…
Consultation on various Special Food funding proposals. Closed (4 pages, 63 KB)
30 July 2010 Proposal relating to the funding of various Special Foods PHARMAC is seeking feedback on a proposal relating the listing of various special foods in the Pharmaceutical Schedule. PHARMAC and Abbott Laboratories have entered into a provisional agreement…
Proposal for radiological contrast media. Closed (2 pages, 117 KB)
30 July 2010 Proposal for radiological contrast media PHARMAC is seeking feedback on a proposal to list in Part II of Section H of the Pharmaceutical Schedule, or amend the listing of, a number of radiological contrast media as part…
Proposal to fund a new topical anti-acne treatment (adapalene). Closed (2 pages, 57 KB)
30 July 2010 Proposal to fund a new topical anti-acne treatment (adapalene) and to fully fund urea cream PHARMAC is seeking feedback on a proposal to fully fund a topical retinoid (adapalene cream and gel) as a further first-line therapy…
Proposal to fund erlotinib and widen access to rituximab, capecitabine and mycophenolate. Closed (15 pages, 112 KB)
30 July 2010 Proposal to fund erlotinib and to widen funded access to rituximab, capecitabine and mycophenolate mofetil PHARMAC is seeking feedback on a proposal to: 1. 2. fund erlotinib (Tarceva) from 1 October 2010 for second line treatment of…
Proposal to list a new brand of sodium chloride in Section H. Closed (1 page, 49 KB)
30 July 2010 Proposal to list a new brand of sodium chloride in Section H PHARMAC is seeking feedback on a proposal to list the Freeflex brand of sodium chloride 0.9% infusion in Part II of Section H from 1…
Proposal to reference price loperamide hydrochloride presentations. Closed (2 pages, 50 KB)
30 July 2010 Proposal to reference price loperamide hydrochloride presentations PHARMAC is seeking feedback on a proposal to reference price loperamide hydrochloride tablets to loperamide hydrochloride capsules. Loperamide capsules will be fully funded from 1 October 2010. If approved, this…
Proposal to widen access to temozolomide. Closed (2 pages, 150 KB)
29 July 2010 Proposal to widen access to temozolomide PHARMAC is seeking feedback on a proposal to widen funded access to temozolomide from 1 October 2010 to include the treatment of patients with newly diagnosed anaplastic astrocytoma. We also propose…
Consultation letter - Ezetrol, Vytorin, Tolvon, Ovestin. Closed (6 pages, 98 KB)
27 July 2010 Consultation on a proposal relating to Ezetimibe, Ezetimibe with Simvastatin, Mianserin Hydrochloride and Oestriol PHARMAC is seeking feedback on a proposal which would result in greater funded access to the cholesterol lowering pharmaceutical ezetimibe and also greater…
Proposal to fund modafinil (Modavigil) for narcolepsy. Closed (2 pages, 108 KB)
23 July 2010 Proposal to fund modafinil (Modavigil) for narcolepsy PHARMAC is seeking feedback on a proposal to fund modafinil (Modavigil) from 1 October 2010 for patients with narcolepsy through a provisional agreement with CSL Biotherapies (NZ) Limited. Under this…
Proposal to list various API Consumer Brands products in the Pharmaceutical Schedule. Closed (2 pages, 147 KB)
16 July 2010 Proposal to list various API Consumer Brands products in the Pharmaceutical Schedule PHARMAC is seeking feedback on a proposal to list another brand of triclosan and a range of other dermatological products in the Pharmaceutical Schedule. In…
Tender 2010 - letter to Medical Groups, DHB Hospital Pharmacies and interested parties - closed (25 pages, 407 KB)
14 July 2010 2010/11 Multi-product Tender PHARMAC is seeking feedback from Medical Groups, DHB Hospital Pharmacies and other Interested Parties on: A proposal to tender certain pharmaceuticals for sole supply; and The draft process and terms and conditions for the…
Tender 2010 - letter to pharmaceutical suppliers and interested parties - ACPs closed, other responses closed (26 pages, 326 KB)
14 July 2010 2010/11 Multi-product Tender PHARMAC is seeking feedback from pharmaceutical suppliers and interested parties on: · · · A proposal to tender certain pharmaceuticals for sole supply; The draft process and terms and conditions for the Invitation to…
Proposal to fund meloxicam and mitomycin. Closed (3 pages, 56 KB)
12 July 2010 Proposal to fund meloxicam and mitomycin PHARMAC is seeking feedback on a proposal involving the funding of Arrow Pharmaceuticals’ brands of mitomycin C 5 mg injection and meloxicam 7.5 mg tablets. In summary: • • mitomycin C…
